Actinic Keratosis Research Articles

Comparison of the IHC Expression of p16, p53, and MIB-1 in Extragenital Skin Bowenoid Lesions With High- and Low- Chronic Sun Damage.

Bowen disease and bowenoid actinic keratosis are difficult to distinguish due to overlapping histopathology. This study evaluates the role of p16, p53, and MIB-1 staining patterns in differentiating high-chronic sun damage (H-CSD) and low-chronic sun damage bowenoid lesions. Sixty extragenital in situ squamous cell carcinomas were included. Lesions with elastosis were considered H-CSD. P16, p53, and MIB-1 staining patterns were classified as block, gradient, or focal. Seventy-two percent of lesions were H-CSD. Full-thickness dysplasia was observed in all lesions, and basal layer involvement in 97%. P16 staining was positive in 80%, matching areas of higher atypia, with block pattern more frequent in H-CSD (58% vs. 47%, P = 0.047). P53 was positive in 47%, with block pattern more common in H-CSD (40% vs. 18%, P = 0.02). MIB-1 was positive in all cases. P16 and MIB-1 patterns coincided in 75%, independently of sun exposure. P16 and p53 expression may be less frequent in bowenoid lesions than previously described. Histopathological features like basal layer and adnexal or follicular involvement may not differentiate H-CSD from low-chronic sun damage lesions or Bowen disease from bowenoid actinic keratosis. Variations in p16, p53, and MIB-1 staining could indicate different dysplasia pathways, although further studies are needed to clarify their prognostic significance.

The evolving landscape of laser-based skin cancer prevention.

In the United States, 1 in 5 Americans develop keratinocyte carcinoma (KC) by age 70, placing the disease among the five most expensive cancers based on Medicare expenditure. Current preventative measures have failed to stem rising KC rates, highlighting the need for alternative strategies. Evolving evidence indicates that lasers conventionally used to treat photoaging, may provide protective effects against the development of KC and precursor lesion, actinic keratosis (AK). This review first delves into existing evidence on fractional infrared laser-based KC and AK prevention. Next, the work discusses potential underlying mechanisms that might explain fractional infrared lasers' prophylactic effects. A comprehensive literature search of PubMed and Web of Science databases was conducted from inception to April 2024 using preselected search terms. Interventional human and animal studies, epidemiological analyses, and case reports on fractional infrared laser-based prevention of KC or AK were screened according to predefined inclusion/exclusion criteria. Included evidence demonstrates that ablative fractional lasers reduce and delay development of AK/KC, shown in two controlled trials of photodamaged patients and two murine studies (i.e. Er: YSGG and CO2 lasers). Weaker evidence of KC prevention by nonablative infrared lasers is provided by a retrospective cohort study. In the laser literature, three mechanisms are proposed to drive these prophylactic effects, including the ability of infrared lasers to (i) remove DNA-damaged epidermal cells, (ii) activate the insulin-like growth factor-1 pathway by reducing fibroblast senescence, and (iii) initiate immunomodulating effects. Based on current evidence, infrared fractional lasers show promise particularly for secondary KC prevention in photodamaged populations.

Cutaneous leishmaniasis misdiagnosed as epithelial skin cancer

Cutaneous leishmaniasis, transmitted by sand flies of the genus Phlebotomus, is one of the most important traveler's dermatoses in Germany. In recent years, an increased incidence of the disease has been observed in travelers returning from endemic areas, including the Mediterranean region of Spain and Italy. In these regions, Leishmania infantum belonging to the Leishmania donovani complex is characteristically the most frequently detected pathogen. We herein report two cases of cutaneous leishmaniasis caused by Leishmania infantum with solitary or multilocular lesions, initially misdiagnosed as actinic keratosis and cutaneous squamous cell carcinoma.

Topical Photodynamic Therapy in a Medical Centre: The Scottish Dermatology Experience.

Topical photodynamic therapy (PDT) is widely used in dermatology for treating superficial non-melanoma skin cancer (NMSC) and dysplasia. This study aims to assess real-world outcomes of PDT in a Scottish dermatology service. We retrospectively reviewed patients with superficial NMSC and dysplasia who underwent conventional and daylight PDT at the Photobiology Unit, Dundee, Scotland. A total of 705 patients with 2108 NMSC and precancerous skin lesions underwent conventional PDT. Clearance at 12 months was achieved in 53.4% of actinic keratoses (AK), 71.3% of Bowenoid AK, 86.4% of Bowen's disease (BD), 89.0% of superficial basal cell carcinoma (BCC), and 89.7% of nodular BCC. On multivariate analysis, small lesion size and thin histological tumour thickness of superficial BCC were features, which were associated with likelihood of achieving clearance after PDT. Female sex, head/neck sites, larger lesion size, strong pre-treatment fluorescence intensity, fluorescence specificity, prominent treatment-induced erythema and an urticarial reaction were associated with moderate to severe pain during PDT. Daylight PDT for 77 AK patients (158 treatments) showed excellent or good outcomes in 63.3% of lesions. Higher visible light exposure is correlated with better treatment outcomes. In real-life settings, whilst the PDT response rates of BD and selected BCC are high and consistent with clinical trial outcomes, the efficacy rates for AK appear lower than expected. This emphasizes the need for realistic expectations in chronic disease management. Through review over a prolonged period, factors associated with PDT tolerability and outcomes were identified, allowing predictive utilisation for optimizing patient-centred PDT regimens.

Re-thinking some anatomical pathology classifications with an emphasis on solar keratoses and basal cell carcinomas

Re-thinking some anatomical pathology classifications with an emphasis on solar keratoses and basal cell carcinomas

Association between use of antihypertensives and treatment of actinic keratoses: A TriNetX population- based study.

Association between use of antihypertensives and treatment of actinic keratoses: A TriNetX population- based study.

Comparative Efficacy and Tolerability of Imiquimod 3.75% Cream vs 5-Fluorouracil 4% cream in the Treatment of Actinic Keratosis: A Split-Face Study

Introduction: Actinic keratosis (AK) is a common precancerous skin lesion that arises on chronically UV-exposed skin and can progress to keratinocyte carcinoma. Objective: The aim of this study is to compare efficacy, safety, local skin reaction, time to wound closure, and patient preference of imiquimod (IMQ) 3.75% vs 5-fluorouracil (5-FU) 4% cream treatment for AKs. Methods: Two symmetrical contralateral areas of approximately 25 cm2 harboring a similar (≥5) number of AKs were selected and randomly assigned to IMQ 3.75% or 5- FU 4% cream treatment. The total number of AKs for each patient, was evaluated at baseline (T0) and 90 days after the end of treatments (T1). Local skin reaction (LSR) score was registered the day after the end of both treatments. Complete remission rate of lesions, cosmetic outcome, and patient preference of treatment were assessed after 90 days (T1). Results: The mean variation (ΔT0-T1) of AKs was not significantly different in patients treated with IMQ 3.75% and 5-FU 4% (p=0.35). The mean LSR was not significantly different for patients treated with IMQ 3.75% and 5-FU 4% (p=0.63). No difference in cosmetic outcome was observed in the 2 groups. Patient preference was equally distributed between the treatments. The mean time to wound closure after the end of the treatment was similar after IMQ 3.75% as compared to 5-FU 4% (p=0.83). Conclusions: This study reports a non-superiority of efficacy, tolerability, wound-healing time, and cosmetic outcome of topical IMQ 3.75% treatment compared to topical 5-FU 4% treatment in AK management.

Prebiotic- and Panthenol-Containing Multipurpose Healing Dermocosmetics Post-Cryotherapy for Actinic Keratoses: Results of a Randomized Controlled Trial

Introduction: Actinic keratosis (AK) is a precancerous skin lesion that can progress to keratinocyte carcinoma. Objective: The objective of the study was to evaluate the efficacy of a dermocosmetic (DC) formulation containing prebiotic active ingredients (Aqua Posae Filiformis, a complex made of ferments, sugars, plant extracts, panthenol, madecassoside, and zinc) on healing time and local skin reactions (LSR) following cryotherapy of AKs and to compare the application of DC aand boric acid 3% solution soaks (BA) vs. BA alone. Methods: Seventy-five adult patients presenting with a maximum of 5 isolated AKS on the face and/or scalp and who underwent cryotherapy (T0) were enrolled. Post-treatment, patients initiated the application of BA only or BA followed by DC once daily for 30 days (unblinded 1:1 randomization). The evaluation of efficacy in healing time and cosmetic outcomes was assessed 30 days post-treatment (T2); LSR was evaluated 3 days post-treatment (T1). Results: There was a gain of 4.5 days (40%) in healing time in the BA+DC group compared to the BA group, with a median time of 7 days versus 11.5 days (P<0.0005). Additionally, 50% of lesions in complete response had an excellent cosmetic outcome with BA+DC vs. 20% with BA only. The majority of patients treated with BA+DC had mild LSR vs. moderate LSR with BA, with a median value of 2 vs 3, respectively (P<0.0001). Conclusion: The addition of a prebiotic DC significantly reduced healing time, improved cosmetic outcomes, and minimized LSR post-cryotherapy. No adverse events were reported with this treatment.

Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream

Introduction: Topical imiquimod is a safe and effective treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. The treatment is commonly associated with local inflammatory reactions, while systemic side effects are rare and generally mild. Only few cases of erythema multiforme and Stevens-Johnson syndrome have been described in association with topical imiquimod application. Objective: We present a review of the existing cases of erythema multiforme and Stevens-Johnson syndrome reported in the literature, analyzing the clinical appearance, the histology and the treatment of the lesions. Method: Nine case of erythema multiforme were reported, characterized by cutaneous rash, bullae, crusting, erosive and targetoid lesions, mainly located at the extremities. Mucosal involvement and systemic symptoms were sometimes present. Results: Three cases of Stevens-Johnson syndrome were associated with topical imiquimod. In all cases, the authors reported targetoid lesions and areas of erosion affecting trunk and limbs, associated with systemic symptoms, and, in 2 cases, to mucosal erosions. Conclusions: We hypothesize a possible role of interferon-γ, a cytokine involved in the pathogenesis of both herpes-associated erythema multiforme and Stevens-Johnson syndrome, which is released in response to the administration of imiquimod.

Epidemiology and Management of Actinic Keratosis in France: A General Population Survey (REAKT).

The objective of this retrospective observational study was to estimate the prevalence of actinic keratosis (AK) in individuals aged ≥ 40 years in France, to describe the characteristics of affected patients, and to describe treatments. A representative panel of 20,000 households with ≥ 1 member aged ≥ 40 years were invited to participate. Participants who reported AK lesions diagnosed by a physician were eligible. The study questionnaire collected data on demographics, lesion characteristics, Fitzpatrick phototype, diagnosis, and treatments. In total, 15,246 questionnaires (78.5%) were returned and 639 responders were eligible. The adjusted prevalence of AK was 4.03% (95% CI: 3.73-4.35). Prevalence is probably underestimated due to data collection by self-report and low awareness of AK. 177 participants (27.7%) were aged < 65 years. AK was diagnosed by a dermatologist for 521 participants (81.6%). Some 200 participants (31.3%) had no lesions at the time of the survey and 243 (37.9%) had never been treated; 312 participants (78.6%) were prescribed physical treatment, principally cryotherapy; and 125 (31.5%) were prescribed topical treatment, principally 5-fluorouracil or imiquimod. In conclusion, improving diagnosis of AK in everyday clinical practice is important to ensure that all individuals with AK are treated optimally and encouraged to take sun protection measures to prevent progression to SCC.

From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments

Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer, among which 82% arise from actinic keratosis (AK) characterized by lesions of epidermal keratinocyte dysplasia. It is of great significance to uncover the progression mechanisms from AK to cSCC, which will facilitate the early therapeutic intervention of AK before malignant transformation. Thus, more and more studies are trying to ascertain the potential transformation mechanisms through multi-omics, including genetics, transcriptomics, and epigenetics. In this review, we gave an overview of the specific biomarkers and signaling pathways that may be involved in the pathogenesis from AK to cSCC, pointing out future possible molecular therapies for the early intervention of AK and cSCC. We also discussed current interventions on AK and cSCC, together with future perspectives.

Exploring Anti-Aging Effects of Topical Treatments for Actinic Keratosis

Background and Objectives: Actinic keratosis (AK) is a precancerous cutaneous lesion driven by chronic ultraviolet (UV) exposure, often coexisting with features of photoaging, such as wrinkles and pigmentary irregularities. Recent evidence suggests that treatments for AK may also counteract photoaging through shared molecular pathways, including oxidative stress and inflammation. This narrative review explores the dual benefits of AK therapies, highlighting their potential anti-aging and skin-lightening effects, and implications for improving skin appearance alongside lesion clearance. Materials and Methods: The literature was analyzed to assess the efficacy, mechanisms, and cosmetic outcomes of commonly used AK treatments, including topical agents (5-fluorouracil (5-FU), imiquimod, diclofenac, and tirbanibulin), and photodynamic therapy (PDT). Studies highlighting their effects on photoaged skin, collagen remodeling, pigmentation, and patient satisfaction were reviewed. Results: PDT emerged as the most validated treatment, demonstrating improved collagen synthesis, skin texture, and pigmentation. 5-FU showed remodeling of the dermal matrix and increased procollagen levels, but local skin reactions represent a major limitation. Imiquimod enhanced dermal fibroplasia and reduced solar elastosis, while diclofenac provided mild photodamage improvements with minimal adverse effects. Tirbanibulin showed promising aesthetic outcomes, including skin lightening and a reduction in mottled pigmentation, with favorable tolerability. Conclusions: AK therapies offer a dual-purpose strategy, addressing both precancerous lesions and cosmetic concerns associated with photoaging. While PDT remains the gold standard, emerging agents like tirbanibulin ointment exhibit substantial potential. Future research should focus on optimizing treatment protocols and evaluating long-term cosmetic outcomes to enhance patient satisfaction and compliance.

ACTINIC KERATOSIS, SCOPING REVIEW

Introduction: actinic keratoses, also called senile keratoses or solar keratoses, are benign intraepithelial neoplasms common in dermatologic consultation. Individuals with actinic keratoses may present with irregular, reddish, scaly papules or plaques on areas of the body exposed to solar radiation. These dysplastic proliferations of keratinocytes have the potential for malignant transformation and may progress to squamous cell carcinoma. Objective: to detail the current information related to actinic keratosis, etiology, epidemiology, pathophysiology, histopathology, clinical presentation, evaluation, diagnosis, treatment and prognosis. Methodology: a total of 32 articles were analyzed in this review, including review and original articles, as well as clinical cases, of which 21 bibliographies were used because the other articles were not relevant to this study. The sources of information were PubMed, Google Scholar and Cochrane; the terms used to search for information in Spanish, Portuguese and English were: actinic keratosis, solar keratosis, dysplastic proliferations of keratinocytes, squamous cell carcinoma. Results: actinic keratosis is a common condition associated with chronic sun exposure, especially in older people, with a prevalence up to 60 years of age. Exposure to ultraviolet radiation is the main risk factor, and individuals with fair skin, outdoor work or compromised immune systems. Diagnosis is made through clinical observation, dermoscopy and in some cases biopsy. Treatments include options such as cryotherapy, excision, light-based therapies and topical medications such as 5-fluorouracil, with a personalized approach depending on lesion characteristics and patient response. Conclusions: actinic keratosis is a relevant dermatologic condition that requires constant vigilance due to its potential to progress to malignant forms. Preventive education on photoprotection and self-care, together with adequate and personalized treatment, are essential to control the disease and minimize the risk of serious complications, such as carcinoma. KEY WORDS: Keratosis, Dysplasia, Keratinocytes, Carcinoma, Ultraviolet.

SKIN CANCERS IN VIETNAMESE XERODERMA PIGMENTOSUM PATIENTS

Objective: Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder caused by defects in DNA repair, leading to severe photosensitivity and significantly increased risk of skin cancer. This study aimed to investigate the clinical features and characteristics of skin cancers in newly diagnosed XP patients in Vietnam from 2018 to 2022, with the goal of improving diagnosis and management. Methods: We conducted a descriptive cross-sectional study on 36 newly diagnosed XP patients. Diagnosis was based on medical history and clinical examination. Data on the presence of skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), were collected and analyzed. Results: Among the 36 patients, 8 (22.22%) had one or more skin cancers. Six patients had BCCs, and two had SCCs. The mean age at first BCC appearance was 44 ± 18.72 years. One patient presented with multiple BCCs (3 lesions). All BCC cases were treated surgically with good outcomes. The highest number of SCCs (4 lesions) was observed in a 55-year-old man, who also had 20 actinic keratoses (AKs). All patients with BCC or SCC had concurrent AKs. A 16-year-old male, who developed skin cancer at age 9, died due to a giant tumor on his head, representing the youngest case of skin cancer in this cohort. Conclusion: Early diagnosis and management of XP, including sun protection and regular monitoring for skin cancers, are essential for improving patient outcomes. The findings from this study contribute to the development of practical guidelines for diagnosing and managing XP in Vietnam. Received 15 June 2024Revised 06 July 2024Accepted 18 October 2024

Linear porokeratosis and the rationale of combining calcipotriol with 5-fluorouracil

Linear porokeratosis is one of the rare forms of porokeratosis and is also pre-malignant in nature. The term porokeratosis is a misnomer, as it is not a disorder of the sweat gland ducts, but rather a disorder of keratinization. There is no standard of therapy for porokeratosis and many topical therapies exist such as topical retinoids; keratolytics such as salicylic acid and urea; topical vitamin D3 analogs such as calcipotriol and calcipotriene, along with the newer 2% lovastatin creams with or without 2% cholesterol cream. We report this case of linear porokeratosis since we have combined 5% 5-fluorouracil cream and 0.005% calcipotriol ointment for both clinical cure and cancer immunotherapy. Although it is a common combination used in the treatment of actinic keratosis, another premalignant dermatosis, it has been uncommonly used in porokeratosis of Mibelli and never reported to be used in linear porokeratosis.

Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials.

Topical 5-fluorouracil (5-FU), 5% or 4% cream, is recommended among first-line treatments for actinic keratosis (AK). Local skin reactions (LSRs) are an expected and transient response to treatment with 5-FU but can lead to treatment discontinuation when severe. This analysis aimed to investigate whether the severity of LSRs during the treatment was associated with lesion clearance assessed 4 weeks after completing treatment. This post hoc analysis pooled data from two randomised clinical trials (HD-FUP3B-048 and HD-FUP3B-049). Only patients treated with once-daily 5-FU 4% for 4 weeks were considered. Analyses included LSR severity at week 2 and 4 and clearance 4 weeks after completing treatment (week 8). Analysed LSRs were erythema, scaling, oedema, crusting, erosions, stinging and pruritus, which were each categorised as mild, moderate, severe or none. Response was categorised as complete clearance (CC; clearance of all lesions), partial clearance (PC; ≥ 75% clearance) or no clearance (NC; < 75% or for subgroup analyses NC < 100%). Data from 397 patients were included. The median number of AK was 11 (lower quartile Q1 = 7 and upper quartile Q3 = 18) and grades were mild to moderate (86.4% of patients) and severe. At week 8, 321 patients (80.9%) had CC/PC and 76 (19.1%) had NC. Patients who achieved CC/PC had, at baseline, more lesions, a more severe disease and lesions preferentially on the ears/face than patients with NC. In adjusted logistic regression analyses and across all LSR grades, CC/PC at week 8 was associated with occurrence of erythema, oedema, crusting and stinging at week 2 and all LSRs at week 4. Severe erythema observed at week 2 was significantly associated with lesion clearance compared with mild erythema. At week 4, both severe and moderate erythema, moderate scaling and moderate pruritus were significantly associated with lesion clearance at week 8 compared with mild LSRs. Results according to the LSR severity for patients who had 100% clearance are quite similar. Our analysis showed that the severity of LSRs during 5-FU 4% treatment for AK was associated with a higher clearance rate. It appears that severe LSRs did not compromise treatment efficacy. Because LSRs can still be unpleasant, strategies must be developed to relieve patients to allow continued 5-FU 4% application.

AAPM Task Group Report 274: Fluence rate dosimetry for photodynamic therapy (PDT).

Photodynamic therapy (PDT) is a treatment modality clinically approved for several oncologic indications, including esophageal and endobronchial cancers, precancerous conditions including Barrett's esophagus and actinic keratosis, and benign conditions like age-related macular degeneration. While it is currently clinically underused, PDT is an area of significant research interest. Because PDT relies on the absorption of light energy by intrinsic or administered absorbers, the dosimetric quantity of interest is the absorbed energy per unit mass of tissue, proportional to the fluence rate of light in tissue. It has been demonstrated that the fluence rate at the tissue surface may differ significantly from the incident irradiance of light because of multiple scattering and absorption, both of which may vary among patients and tissue types. This report will review the current state-of-the-art fluence rate dosimetry technology. It will describe the two types of detectors currently available for fluence rate measurement, scattering-tip and fluorescence-based detectors, and review their principles of operation. The report will recommend strategies to establish calibration and quality assurance procedures for clinical fluence rate dosimetry equipment, and it will establish guidelines for clinical implementation of fluence rate dosimetry.

Multiple Actinic Keratoses treated with oral capecitabine.

Multiple Actinic Keratoses treated with oral capecitabine.

Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study.

Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer. We examined the skin lesions on their entire body by polarized and nonpolarized dermoscopy. A total of 21 suspicious lesions in the first group and 17 in the second one were removed and histologically analyzed. Twelve (9.4%) cancerous or precancerous lesions were found in the first group: seven (5.5%) basal cell carcinoma (BCC) and five actinic keratosis. The mean time to cancer onset was identified as 22 months after the start of four therapy, with an SD of 18 months, suggesting an earlier onset with respect to the start of therapy in our population. On univariate analysis, age (P = 0.001) and age of psoriasis onset (0.009) were statistically significant. Nine of 17 were skin cancers in the second group. Our study provided real-life evidence of the percentage of patients with skin cancers during therapy with anti-IL mAbs, demonstrating a good safety profile of the investigated drugs.

Computational network analysis of two popular skin cancers provides insights into the molecular mechanisms and reveals common therapeutic targets.

Basal Cell Carcinoma (BCC) and Actinic Keratosis (AK) are prevalent skin conditions with significant health complications. The molecular mechanisms underlying these conditions and their potential shared pathways remain ambiguous despite their prevalence. Therefore, this study aims to elucidate the common molecular pathways and potential therapeutic targets for BCC and AK through comprehensive computational network analysis. Linkage analysis was performed to identify common liable genes between BCC and AK. Protein-protein interactions (PPIs), Topological properties, GO enrichment, pathway enrichment, and gene regulatory network analyses were also performed to reveal potential molecular mechanisms and pathways. Furthermore, we evaluated protein-drug interactions (PDIs) to identify potential therapeutic targets. Our analysis revealed 22 common genes between BCC and AK: TP53, EGFR, CDKN2A, MMP9, PTGS2, VDR, BCL2, MMP2, EZH2, TP63, FOXP3, MSH2, MMP14, FLG, MC1R, CDKN2B, TIMP3, TYR, SOX10, IRF4, KRT17, and NID1. PPI network analysis highlighted TP53 and EGFR as central hubs, validated using RNA-seq data. Co-expression and physical interaction analysis revealed a strong interplay between the common genes at the transcriptional and functional levels. GO analysis identified skin cancer-relevant terms: "skin development", "immune system development", and "response to radiation" as significantly enriched biological processes, while pathway enrichment analysis highlighted several cancer-related pathways enrichment. Gene regulatory network analysis revealed complex interactions between genes, miRNAs, and transcription factors, with TP53, BCL2, and EGFR playing central roles. PDI network analysis identified ibuprofen as a potential therapeutic agent targeting PTGS2 and BCL2, while other proteins VDR, MMP2, MMP9, and TYR showed interactions with multiple drugs. This computational analysis provides valuable insights into the shared molecular mechanisms of BCC and AK, revealing common pathways and potential therapeutic targets for developing novel treatment strategies and repurposing existing drugs for these prevalent skin cancers. Therefore, these findings may guide future research in understanding and developing targeted therapies for both conditions.